Despite periodic geopolitical tensions and economic volatility, multinational pharmaceutical companies including Pfizer, Sanofi, Novartis, AstraZeneca, Roche, and Abbott continue expanding manufacturing, packaging, research collaborations, and commercial operations across the region. Rather than viewing MENA solely as a sales market, global pharmaceutical companies increasingly see the region as a strategic manufacturing and export platform linking Europe, Africa, and Asia. Together, these complementary strategies are transforming MENA into a diversified regional pharmaceutical manufacturing ecosystem rather than a collection of isolated national markets. Countries with strong regulatory systems and expanding pharmaceutical capabilities are well positioned to capture a growing share of this production. ConclusionGlobal pharmaceutical companies are expanding manufacturing across MENA because the region increasingly offers a compelling combination of commercial growth, industrial policy, and strategic geography.